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The major capsid protein of norovirus GII.4 strains is evolving rapidly, resulting in epidemic strains with altered antigenicity.
GII.4.2006 Minerva strains circulated at pandemic levels in 2006 and persisted at lower levels until 2009. In 2009, a new GII.4
variant, GII.4.2009 New Orleans, emerged and since then has become the predominant strain circulating in human populations.
To determine whether changes in evolving blockade epitopes correlate with the emergence of the GII.4.2009 New Orleans
strains, we compared the antibody reactivity of a panel of mouse monoclonal antibodies (MAbs) against GII.4.2006 and
GII.4.2009 virus-like particles (VLPs). Both anti-GII.4.2006 and GII.4.2009 MAbs effectively differentiated the two strains by
VLP-carbohydrate ligand blockade assay. Most of the GII.4.2006 MAbs preferentially blocked GII.4.2006, while all of the
GII.4.2009 MAbs preferentially blocked GII.4.2009, although 8 of 12 tested blockade MAbs blocked both VLPs. Using mutant
VLPs designed to alter predicted antigenic epitopes, binding of seven of the blockade MAbs was impacted by alterations in
epitope A, identifying residues 294, 296, 297, 298, 368, and 372 as important antigenic sites in these strains. Convalescent-phase
serum collected from a GII.4.2009 outbreak confirmed the immunodominance of epitope A, since alterations of epitope A af-
fected serum reactivity by 40%. These data indicate that the GII.4.2009 New Orleans variant has evolved a key blockade epitope,
possibly allowing for at least partial escape from protective herd immunity and provide epidemiological support for the utility of
monitoring changes in epitope A in emergent strain surveillance.
Noroviruses (NoVs) are the leading cause of severe viral gas-troenteritis worldwide, causing 50% of all acute gastroen-
teritis outbreaks in the United States and Europe (1). Disease se-
verity is usually moderate, but morbidity and mortality rates due
to NoV infection are increasingly becoming evident, with partic-
ularly high tolls taken on children and immunocompromised and
aged populations (2–9), resulting in an estimated 200,000 deaths
per year (10). In addition, postinfectious irritable bowel syndrome
develops in a substantial portion of patients (11). These groups of
people, in addition to military personnel, childcare and health
care providers, and food handlers, would benefit from a NoV vac-
cine. Recent success has been demonstrated for a monovalent
Norwalk virus VLP-based vaccine (12), but significant obstacles
remain for the development of a broadly protective NoV vaccine,
including the lack of a clear understanding of the complex anti-
genic relationships between the many NoV strains and the inter-
action between these strains and the host immune system over
time.
Noroviruses contain positive-sense, single-stranded RNA ge-
nomes, and phylogenetic classification is based on the amino acid
sequence of the major capsid protein encoded by ORF2 (13).
Genogroup I (GI) and GII cause most human infections, and each
genogroup is further subdivided into 9 and 21 different genotypes,
respectively (1, 13). Exogenous expression of ORF2, the major
capsid protein, results in virus-like particle (VLP) self-assembly.
Each particle is composed of 90 copies of the major capsid protein
dimer and a small number of copies of the ORF3-encoded minor
capsid protein (14, 15). The capsid monomer is divided into two
structural domains. The shell domain (S) forms the core of the
particle and the protruding domain (P) extends away from the
central core. The P domain is further divided into two sub-
domains: P1 consists of residues 226 to 278 and residues 406 to
520 and forms the stalks that support the extended, surface-ex-
posed P2 subdomain (residues 279 to 405) (14). The P2 sub-
domain interacts with potential neutralizing/blockade antibodies
and the NoV carbohydrate-binding ligands, the histo-blood
group antigens (HBGAs) (16–22). Coinciding with these func-
tions, changes in the P2 amino acid sequence of GII.4 strains occur
frequently and correlate with the emergence of new epidemic
strains with altered carbohydrate ligand binding and antigenicity
profiles (16, 20, 23–29). The study of neutralization antibodies
and epitopes is hindered by the lack of a cell culture or small
animal model for human norovirus propagation. Therefore, we
developed an in vitro surrogate neutralization assay that measures
the ability of an antibody to block binding of a VLP to a carbohy-
drate ligand (16, 20, 30, 31). The blockade assay has been verified
as a surrogate neutralization assay in infected chimpanzees (32)
and Norwalk virus-infected humans (12, 33). Importantly, the
blockade assay has been shown to differentiate between GII.4
strains antigenically too similar to be distinguished from each
other by traditional EIAs (16, 20, 34). This enhanced sensitivity
has been crucial in mapping GII.4 evolving blockade epitopes.
GII.4 strains have caused the majority of all norovirus out-
breaks over the past 2 decades. Four GII.4 pandemics, each caused
by a newly emergent GII.4 variant strain, have been characterized
using molecular epidemiological methods. Strain US95/96
(GII.4.1997) caused the pandemic that occurred during the mid-
1990s (35, 36). The second pandemic began in 2002 with the
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emergence of the Farmington Hills strain (GII.4.2002) (37), fol-
lowed closely by the third pandemic in 2004 attributed to the
emergence of the Hunter strain (GII.4.2004) (38–40). The most
recent pandemic strain was Minerva 2006b (GII.4.2006), which
emerged in 2006 and quickly replaced other circulating NoVs (5,
39, 41). Most recently, a new GII.4.2006 variant, GII.4.2009 New
Orleans, has been the predominant outbreak strain, although
GII.4.2006 Minerva continues to circulate at low levels (1, 42).
GII.4.2009 New Orleans first emerged in October of 2009 and by
November accounted for 56% of the outbreaks documented by
CaliciNet (42). In comparison, GII.4.2006 Minerva made up only
11% of the cases at that time, implying a circulating strain replace-
ment. The emergence of GII.4.2009 New Orleans did not result in
an increase in norovirus outbreaks, leading Yen et al. to suggest
that GII.4.2009 New Orleans did not target an immunologically
naive population (43).
Comparing the monoclonal antibody (MAb) reactivity of dif-
ferent GII.4 strains that have circulated over the past 2 decades has
clearly demonstrated that new strain emergence is associated with
changes in blockade antibody epitopes (20, 34). We and others
have used bioinformatic tools to predict potential evolving
epitopes. Residues 296 to 298 and residues 393 to 395 are consis-
tently identified by different groups as putative epitopes that
change between epidemic GII.4 strains. Surface residues at posi-
tions 333, 340, 356, 368, 372, 407, and 412 to 413 have also been
predicted as antibody epitopes (16, 23, 24, 27, 38, 44–47). These
amino acids cluster within the P2 subdomain, where they would
be most available on the capsid surface for interactions with anti-
bodies. Although bioinformatic predictions are useful, few studies
have tested these predictions. Allen et al. (46) compared the VLP-
binding reactivity of five MAbs against one pre- and one post-
2002 pandemic GII.4 strain and found two conformational
epitopes as differing between the two strains. Site A includes
amino acids 294 to 296. Site B includes amino acids 393 to 395 and
confirmed residue 395 as an important antigenic determinant in
the GII.4.2002 Farmington Hills strain (16). Further, our group
has used both human and mouse anti-NoV MAbs coupled with
molecular biology approaches to exchange predicted epitopes be-
tween GII.4 strain backbones to identify evolving blockade
epitopes between GII.4 strains that have circulated from 1987 un-
til 2009. Using this novel approach we have identified three evolv-
ing blockade GII.4 antibody epitopes (20–22). Epitope A is com-
prised of amino acids 294, 296 to 298, 368, and 372 and is a highly
variable blockade epitope that changes with new GII.4 strain
emergence. Monoclonal human and mouse antibodies against
epitope A have been described as highly strain selective, lacking
reactivity to other GII.4 strains chronologically removed from the
immunizing strain. GII.4.2006 and GII.4.2009 were found to dif-
fer in reactivity to a human MAb targeting epitope A, establishing
a difference in human neutralizing epitopes between these two
strains and supporting escape from herd immunity by antigenic
variation at neutralizing epitopes as a mechanism for new NoV
strain emergence. Epitope D (residues 393 to 395) has also been
confirmed as an evolving blockade epitope using human anti-
NoV MAbs. These findings are particularly interesting as epitope
D has been shown to modulate HBGA binding of GII.4 strains,
supporting the suggested correlation between epitope escape from
herd immunity and altered HBGA binding (16). Mouse MAbs
have confirmed epitope E (amino acids 407, 412, and 413) as a
GII.4.2002 Farmington Hills-specific blockade epitope (21). Im-
portantly, these empirical studies have validated our approach to
predict evolving GII.4 blockade epitopes.
Epidemiological studies of NoV outbreaks, including sequence
analysis of outbreak strains, coupled with human anti-NoV MAbs
that differentiate GII.4 Minerva and New Orleans strains, indicate
that by 2009 the GII.4.2006 Minerva pandemic NoV strain was
being replaced by the GII.4.2009 New Orleans strain. This strain
replacement pattern is consistent with NoV strain epochal evolu-
tion. Based on documented changes in surrogate neutralization
epitopes of previously emerged GII.4 strains, GII.4.2009 is likely a
herd immunity escape variant of GII.4.2006. To test this hypoth-
esis, we compared the antigenic features of GII.4.2006 and
GII.4.2009 using MAbs developed to each VLP and polyclonal sera
collected during a GII.4.2009 outbreak. MAbs coupled with
epitope altered VLPs identified epitope A as a varying blockade
epitope between GII.4.2006 and GII.4.2009. Confirming the im-
portance of epitope A in the polyclonal immune response, ca. 40%
of the antibody blockade reactivity in a set of GII.4.2009 outbreak
sera was directed against epitope A. These data support the hy-
pothesis that NoV GII.4 strain emergence correlates with changes
in evolving blockade epitopes.
MATERIALS AND METHODS
VLPs. For all constructs except GII.4.2009, the synthetically derived,
epitope-engineered or outbreak strain ORF2 genes were inserted directly
into the VEE replicon vector for the production of virus replicon particles
(VRPs) as previously described by our group (20, 22). Virus-like particles
(VLPs) were expressed in VRP-infected BHK cells and purified by velocity
sedimentation in sucrose, followed by simultaneous concentration and
dialysis into phosphate-buffered saline (PBS) using a 100-kDa MWCO
centrifugal filter units (Millipore). GII.4.2009 (21) VLPs were expressed in
the baculovirus system, concentrated by centrifugation through 40% su-
crose, and purified by cesium chloride gradient centrifugation. VLPs were
resuspended in PBS. VLP protein concentrations were determined by a
BCA protein assay (Pierce, Rockford, IL). The structural integrity of
epitope engineered VLPs was confirmed by electron microscopy, enzyme-
linked immunosorbent assay (ELISA), and carbohydrate binding as de-
scribed previously (20).
EIAs. Mouse MAb reactivity was determined by enzyme immunoas-
say (EIA), as reported (20, 21). Briefly, plates were coated at 1 g of
VLP/ml in PBS before the addition of 1 g of purified IgG/ml. Primary
antibody incubation was followed by anti-mouse IgG-HRP (GE Health-
care) and color development with One-Step Ultra TMB ELISA HRP sub-
strate solution (Thermo Fisher). Each step was followed by washing with
PBS– 0.05% Tween 20, and all antibodies were diluted in 5% dry milk in
PBS– 0.05% Tween 20. The data shown represent the average of at least
three replicates and are representative of similar data from at least two
independent trials. Establishment of EIAs using new MAbs included PBS-
coated wells as negative controls and polyclonal anti-norovirus mouse
sera as positive controls. Antibodies were considered positive for reactiv-
ity if the mean optical density at 450 nm after background subtraction for
VLP-coated wells was 0.2 (48).
VLP-carbohydrate ligand-binding antibody blockade assays. Pig
gastric mucin type III (PGM; Sigma Chemicals) has been validated as a
substrate for NoV VLP antibody blockade assays (21, 22). PGM con-
tains relatively high levels of H and A antigen and more moderate
levels of Lewis Y antigen (21). The VLPs used in the blockade assays in
the present study bind to both PGM and synthetic biotinylated-HBGA,
and binding to PGM is consistent with synthetic Bi-HBGA binding
profiles for -1,2-fucose (H antigen) and -1,4-fucose (Lewis antigen)
containing molecules (16, 21, 49). For blockade assays, PGM was sol-
vated in PBS at 5 mg/ml, coated onto EIA plates at 10 g/ml in PBS for
4 h, and blocked overnight at 4°C in 5% dry milk in PBS– 0.05% Tween
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20. VLPs (0.5 g/ml) were pretreated with decreasing concentrations
of test MAb or outbreak sera for 1 h at room temperature before being
added to the carbohydrate ligand-coated plates for 1 h. Bound VLP
were detected by a rabbit anti-GII norovirus polyclonal sera made
from hyperimmunization with either GII.4.2009 or a cocktail of
GII.4.1997, GII.3.1999, GII.1.1976, and GII.2.1976 VLPs, followed by
anti-rabbit IgG-HRP (GE Healthcare) and color developed with
1-Step Ultra TMB ELISA HRP substrate solution (Thermo Fisher).
The percent control binding was defined as the binding level in the
presence of antibody pretreatment compared to the binding level in
the absence of antibody pretreatment multiplied by 100. All incuba-
tions were performed at room temperature. Each step was followed by
washing with PBS– 0.05% Tween 20, and all reagents were diluted in
5% dry milk in PBS– 0.05% Tween 20. All antibodies were tested for
blockade potential against GII.4 VLPs at 2-fold serial dilutions ranging
from 0.08 to 2 g of MAb/ml or 0.008 to 1% outbreak serum. Addi-
tional concentrations of purified antibodies were tested if needed to
complete the sigmoid dose-response curve. The data shown represent
the averages of at least two replicates and are representative of similar
data from at least two independent trials. Blockade data were fit using
sigmoidal dose-response analysis of nonlinear data in GraphPad
Prism. The 50% effective concentration (EC50) values were calculated
for antibodies that demonstrated a dose-dependent (Hill slope 
0.7) blockade of at least 50% at the dilution series tested. MAbs that
did not block 50% of binding at the highest dilution tested were as-
signed an EC50 of 2 the assay upper limit of detection. Standard error
was used to calculate the 95% confidence intervals (CI), and EC50
values between VLPs were compared using one-way analysis of vari-
ance with Dunnett’s post test, when at least three values were com-
pared or a Student t test when only two values were compared. A
difference was considered significant if the P value was 0.05. Of note,
VLP concentrations in blockade assays are in the low nanomolar range
and therefore cannot discriminate between antibodies with subnano-
molar affinities.
Mouse immunization, hybridoma production, and IgG purifica-
tion. MAbs to GII.4.2009 were produced and purified as described earlier
(21). Swiss-Webster mice were immunized on days 0, 20, 40, and 80 with
50 g of VLP in PBS plus 50 l of GERBU adjuvant (Fisher Scientific) for
a total of 100 l, and splenocytes were fused on day 84. The resulting
hybridomas underwent two rounds of limited dilution subcloning, were
isotyped (Roche), and were purified by protein G chromatography (GE
Healthcare).
Commercial MAbs. Commercial MAbs MAB223P, MAB224P,
MAB225P, and MAB226P were developed against GII.4.2006 VLPs in
collaboration with Maine Biotechnology (Portland, ME).
GII.4 outbreak serum samples. Deidentified convalescent-phase se-
rum samples from eight subjects infected with GII.4.2009 during an out-
break that occurred in March 2010 were studied. Acute- and convales-
cent-phase serum samples were collected 3 to 4 days and 21 days after the
onset of illness, respectively. Infection was defined as (i) IgA seroconver-
sion as measured by EIA against GII.4.2009-VLPs and (ii) virus shedding
in stool samples as detected by GI and GII NoV TaqMan real-time reverse
transcription-PCR (RT-PCR) (42). Norovirus-positive samples were
genotyped by sequencing the RT-PCR product from diagnostic regions C
and D (50, 51). Sequence alignment of the outbreak strain and reference
NoV genotypes was performed using the CLUSTAL W algorithm. Phylo-
genetic analysis was performed using TreeCon software (52), and phylo-
genetic trees were constructed using the neighbor-joining method. The P2
subdomain for each positive sample was amplified and sequenced (42). A
P2 consensus sequence for the outbreak and P2 sequences of representa-
tive GII.4 variants (GII.4 Bristol [1993], GII.4 Farmington Hills [2002],
GII.4 Hunter [2004], GII.4 Osaka, GII.4 Yerseke [2006a], GII.4 Minerva
[2006b], and GII.4 New Orleans [2009]) were aligned, and phylogenetic
analysis was performed as described above.
RESULTS
MAb antigenic differentiation between pandemic GII.4.2006
Minerva and epidemic GII.4.2009 New Orleans. Recent studies
of GII.4 NoV antigenicity clearly indicate that new strain emer-
gence is associated with changes in blockade epitopes (20–22).
The emergence of GII.4.2009 New Orleans provides an opportu-
nity to test this hypothesis in the context of a currently circulating
strain. Previously, we characterized nine mouse MAbs that block
GII.4 VLP interaction with carbohydrate ligand, i.e., MAbs that
potentially recognize neutralization epitopes. To further charac-
terize these MAbs and evaluate their utility in distinguishing be-
tween GII.4.2006 and GII.4.2009 VLPs as antigenic variants, we
compared the EIA reactivity of GII.4.2006 and GII.4.2009 VLPs
with each blockade mouse anti-GII.4 NoV MAb. MAbs
GII.4.1987.G1, GII.4.1987.G4, and GII.4.1987.G5 (22, 34) and
GII.4.2002.G6 (21) do not recognize GII.4.2006 or GII.4.2009
VLP by EIA, whereas MAbs GII.4.2006.G2, GII.4.2006.G3,
GII.4.2006.G4, GII.4.2006.G6, GII.4.2006.G7, and GII.4.2002.G5
(21, 22, 34) demonstrated EIA reactivity with both GII.4.2006 and
GII.4.2009 (data not shown). Thus, EIA reactivity to our mouse
MAbs was insufficient to identify differential blockade epitopes
between GII.4.2006 and GII.4.2009, since each MAb reacted with
both VLPs similarly. Therefore, we expanded the pool of tested
MAbs to include four new, commercially available mouse anti-
GII.4.2006 MAbs (Table 1). First, we characterized these MAbs for
reactivity to an assortment of NoV VLPs, including strains from
both genogroups and a set of time-ordered GII.4 VLPs (20). All
four commercial MAbs demonstrated broad reactivity with GII.4
time-ordered VLPs. MBS224P detected GII.4.2002 through
GII.4.2009 VLPs. MBS225P and MBS226P detected the GII.4
panel and additional GII VLPs but neither GI.1.1968 nor
GII.3.1999 (Table 1). These reactivity patterns have been de-
scribed for anti-GII.4.2006 MAbs previously (34). Importantly,
MAb MBS223P recognized GII.4.1987 through GII.4.2006 VLPs
but did not recognize GII.4.2009, providing evidence at the
epitope level that GII.4.2006 and GII.4.2009 have some distinct
antigenic profiles, as described for human anti-NoV MAbs (20).
Divergence of GII4.2009 New Orleans from GII.4.2006 Mi-
nerva is associated with evolving antibody blockade epitopes.
EIA reactivity to MAbs demonstrates that GII.4.2006 and
GII.4.2009 have distinct antigenic profiles but the high degree of
similarity between the two strains for most of the MAbs tested
TABLE 1 VLP EIA reactivity of commercial anti-GII.4.2006 MAbs
MAb
VLP reactivity
MBS223P MBS224P MBS225P MBS226P
VLP
GI.1.1968 – – – –
GII.1.1971 – –  
GII.2.1976 – –  
GII.3.1999 – – – –
GII.4.1987  –  
GII.4.1997  –  
GII.4.2002    
GII.4.2004    
GII.4.2005    
GII.4.2006    
GII.4.2009 –   
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suggests that a more sensitive measure of antigenic variation is
required to identify functional antigenic changes. The antibody-
mediated VLP-carbohydrate blockade assay measures the poten-
tial neutralization activity of an antibody and has proven to be
highly differential between similar GII.4 NoV strains (16, 20).
Therefore, each of the above-described MAbs was tested for
blockade activity against both GII.4.2006 and GII.4.2009, and the
EC50 values for each VLP were calculated for comparison (Fig. 1).
When potential neutralization was measured instead of EIA reac-
tivity, five of the MAbs reacted differently with the two VLPs.
MAbs GII.4.2006.G3 and GII.4.2006.G4 blocked both VLPs sim-
ilarly. GII.4.2006.G2 and GII.4.2006.G6 blocked GII.4.2006 at sig-
nificantly lower titers than GII.4.2009. Conversely, GII.4.2006.G7,
GII.4.2002.G5, and MBS224P blocked GII.4.2009 at significantly
lower titers than GII.4.2006. MBS223P, MBS225P, and MBS226P
did not block the interaction of either VLP with carbohydrate
ligand at 4 g/ml, indicating that these MAbs do not recognize a
neutralizing epitope in either VLP, although the differential EIA
reactivity of MBS223P in the absence of blockade activity indicates
that GII.4.2006 and GII.4.2009 vary in at least one nonblockade
epitope. Of the seven blockade MAbs tested, five differentiate
GII.4.2006 from GII.4.2009 at potentially neutralizing epitopes.
These data support the hypothesis that the emergence of
GII.4.2009 is associated with changes in antibody blockade
epitopes.
NoV blockade antibodies primarily recognize epitopes within
the P2 subdomain of the major capsid protein (20–22, 53).
GII.4.2006 Minerva and GII.4.2009 New Orleans share 88%
amino acid similarity within the P2 subdomain. Despite this high
degree of similarity, the two strains vary at two previously identi-
fied blockade epitopes (Fig. 2) (20). Epitope E varies at V413I, a
conserved amino acid change. Epitope A varies at A294P, S368A,
and E372D, three of the six amino acids that comprise this immu-
nodominant epitope (20, 22). To test whether variation in epitope
A, D, or E accounts for the differences between GII.4.2006 and
GII.4.2009 identified in blockade assays (Fig. 1), each blockade
MAb was screened for EIA reactivity to GII.4.2006 VLPs contain-
ing alterations in blockade epitopes A, D, and E, previously con-
firmed as blockade antibody targets (20–22). In each case the
GII.4.2006 epitope amino acids were replaced with the amino ac-
ids found in the GII.4.1987 epitope (Fig. 2). Binding of
GII.4.2006.G4 and GII.4.2006.G7 was eliminated by exchange of
epitope A amino acids found in of GII.4.2006 with the amino acids
found in epitope A of 1987 (GII.4.2006/1987A), supporting pre-
vious findings indicating that GII.4.2006.G2, GII.4.2006.G3,
GII.4.2006.G4, and GII.4.2006.G7 binding is impacted by changes
in epitope A of GII.4.2006 (22; data not shown). Exchange of
epitopes D and E within GII.4.2006 did not eliminate binding of
any of the MAbs (data not shown).
Single dilution EIAs were insufficient to identify epitopes for
any of the other blockade MAbs. Therefore, we analyzed the effect
of epitope exchange on the blockade activity of each blockade
MAb. In addition to the epitope exchange VLPs previously de-
scribed, we constructed an additional epitope-exchanged VLP,
GII.4.2006/2009A, comprised of GII.4.2006 backbone gene with
the epitope A residue sequences replaced by the epitope A residue
sequences of GII.4.2009 (Fig. 2). This chimeric VLP has three
common epitope A amino acid residues (residues 296, 297, and
298) and three amino acid differences (residues 294, 368, and 372)
between GII.4.2006 and GII.4.2009. This additional epitope A
variant was designed to allow fine mapping of the residues essen-
tial for MAb blocking of epitope A. In contrast to the less-discrim-
inating EIA, surrogate neutralization assays identified epitope A
amino acids as required for blockade activity of all of the MAbs
that blocked GII.4.2006. GII.4.2006.G2, GII.4.2006.G3,
GII.4.2006.G4, and GII.4.2006.G6 all lost blockade activity when
the GII.4.2006 epitope A sequence was replaced with the epitope A
sequence found in GII.4.1987 (GII.4.2006/1987A, Fig. 3A and
Table 2). Significant amounts of blockade activity were restored to
these antibodies when only three amino acids were replaced (res-
idues 294, 368, and 372 in GII.4.2006/2009A). These results indi-
cate that GII.4.2006.G2, GII.4.2006.G3, GII.4.2006.G4, and
GII.4.2006.G6 all recognize epitope A, and positions 296, 297, and
298 are essential for antibody blockade activity but insufficient to
reconstitute GII.4.2006 blockade completely, since significantly
more antibody was needed to block GII.4.2006/2009A than
GII.4.2006. Further, blockade activity of GII.4.2006.G7 was ab-
lated by exchange of amino acids 294, 297, 298, 368, and 372 in
epitope A (GII.4.2006/1987A), but blockade activity was not sig-
nificantly changed by exchange of amino acids 294, 368, and 372
(GII.4.2006/2009A). This demonstrates that GII.4.2006.G7 recog-
nizes epitope A and that amino acids 296, 297, 298 are not only
essential for blockade activity but also account for most of the
activity, since GII.4.2006/2009A blockade was not significantly
different from GII.4.2006 (Fig. 3B). Neither GII.4.2002.G5 nor
MBS224P blocked GII.4.2006 (Fig. 1) and, subsequently, the ex-
change of epitope A, D, or E amino acids had no significant impact
on blockade activity of these MAbs (Fig. 3C, Table 2, and data not
shown). Further, although both of these MAbs block GII.4.2009,
the exchange of GII.4.2009 epitope A into the GII.4.2006 back-
bone did not confer blockade of GII.4.2006, clearly indicating that
GII.4.2002.G5 and MBS224P are not directed against epitope A
but do target a blockade epitope that differentiates between
GII.4.2006 and GII.4.2009.
Anti-GII.4.2009 New Orleans MAbs target blockade epitopes
and differentiate GII.4.2006 from GII.4.2009. To broaden the
FIG 1 MAbs that recognize evolving GII.4 blockade epitopes distinguish
GII.4.2006 from GII.4.2009. MAbs were assayed for ability to block GII.4.2006
and GII.4.2009 VLP interaction with carbohydrate ligand. Sigmoidal curves
were fit to the mean percent control binding (percent of VLP bound to PGM in
the presence of antibody pretreatment compared to the amount of VLP bound
in the absence of antibody pretreatment), and the mean EC50 (g/ml) titer for
blockade of GII.4.2006 Minerva () and GII.4.2009 New Orleans (Œ) was
calculated. Error bars represent the 95% CI. *, The EC50 blockade titer for
GII.4.2009 is significantly different from the EC50 for GII.4.2006. Nonblock-
ade MAbs were assigned an EC50 of 5 g/ml for statistical analysis and are
denoted by data markers on the graph above the upper limit of detection
(dashed line) for visual comparison.
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antibody pool and potentially identify additional evolving block-
ade epitopes specific for GII.4.2009, we hyperimmunized mice
with GII.4.2009 VLPs and developed five anti-GII.4.2009 mouse
IgG MAbs. This panel of MAbs had limited EIA reactivity with
non-GII.4 VLPs (data not shown). None of the anti-GII.4.2009
MAbs reacted by EIA with NoV VLPs outside GII.4 or with
any GII.4 VLP that circulated before 2004. NO37 reacted by EIA
with GII.4.2005, GII.4.2006, and GII.4.2009. NO52 reacted with
GII.4.2005 and GII.4.2009 but not with GII.4.2006. NO193 re-
acted with GII.4.2004, GII.4.2005, GII.4.2006, and GII.4.2009,
while NO66 and NO224 exclusively recognized GII.4.2009. The
tight GII.4.2009 MAb EIA reactivity profile was maintained in
blockade assays when MAbs were tested against both GII.4.2006
and GII.4.2009 and the mean EC50 values for each VLP calculated
for comparison (Fig. 4). All five MAbs blocked homotypic
GII.4.2009 (mean EC50 range 	 0.0641 to 0.2821 g/ml). Only
NO37 and NO52 blocked GII.4.2006, and both MAbs required
significantly more antibody to block GII.4.2006 than GII.4.2009
(P  0.05). NO193, NO66, and NO224 did not block GII.4.2006 at
the MAb concentrations tested. Therefore, all five GII.4.2009
MAbs differentiated between GII.4.2006 Minerva and GII.4.2009
New Orleans VLPs in blockade assays. GII.4.2009 EIA and block-
ade data demonstrated that GII.4.2006 and GII.4.2009 may vary in
at least three neutralization epitopes.
To potentially identify these differential blockade epitopes, the
GII.4.2009 MAbs were tested for EIA reactivity to the GII.4.2006
epitope-exchange VLPs (data not shown). By EIA, NO37 reacted
positively with each of the epitope-exchanged VLPs except
GII.4.2006/1987A. Further, NO37 required significantly more
MAb to block GII.4.2006 than homotypic GII.4.2009. Exchange of
five epitope A amino acids (GII.4.2006/1987A) ablated the block-
ade activity of NO37 (Fig. 5A), identifying epitope A as a target for
NO37. Exchange of only three amino acids from GII.4.2009
epitope A into GII.4.2006 (GII.4.2006/2009A) increased the
blockade activity of NO37 to levels similar to the GII.4.2006
blockade, indicating that the amino acids in common between
GII.4.2006 and GII.4.2006/2009A (i.e., amino acids 296, 297, and
298) are essential and sufficient for NO37 blockade activity of
these VLPs. Supporting the importance of these sequential amino
acids in antibody recognition, NO37 was the only MAb of 16
tested that detected VLPs by Western blot analysis (data not
shown). By single dilution EIA, NO52 did not react with
GII.4.2006 and consequently did not react with any of the epitope-
exchanged VLPs (data not shown). However, NO52 did weakly
block GII.4.2006 (Fig. 4 and 5B), confirming the increased sensi-
tivity of the blockade assay compared to the single-dilution EIA.
Exchange of five epitope A amino acids (GII.4.2006/1987A) ab-
lated blockade activity of NO52, identifying epitope A as the an-
FIG 2 Amino acid sequence (A) and structural location (B) of confirmed GII.4 evolving blockade epitopes in GII.4 VLPs used in the present study.
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tibody target. In contrast to the effect on NO37 binding, exchange
of the three GII.4.2009 epitope A amino acids (294, 368, and 372)
into GII.4.2006 (GII.4.2006/2009A) resulted in a significant gain
in blockade activity of NO52 for GII.4.2006, approaching the
GII.4.2009 mean EC50 value (Fig. 5B), identifying residues 294,
368, and 372 as essential for blockade activity of NO52. NO66,
NO193, and NO224 blocked GII.4.2009 but did not block
GII.4.2006. Exchange of the GII.4.2009 epitope A into GII.4.2006
FIG 3 GII.4.2006 blockade MAbs recognition of epitope A. MAbs were assayed for ability to block VLP interaction with carbohydrate ligand. Sigmoidal curves
were fit to the mean percent control binding (i.e., the percentage of VLP bound to PGM in the presence of antibody pretreatment compared to the amount of VLP
bound in the absence of antibody pretreatment) and the mean EC50 (g/ml) titer for blockade of epitope-exchanged VLPs calculated. Error bars represent 95%
CI. *, The mean EC50 blockade titer is significantly different from the mean EC50 for GII.4.2006. Nonblockade MAbs were assigned an EC50 of 5 g/ml for
statistical analysis and are denoted on the graph by data markers above the upper limit of detection (dashed line) for visual comparison. The mean EC50 for the
blockade of epitope-exchanged VLPs identified three epitope A reactivity patterns. (A) The exchange of five amino acids (GII.4.2006/1987A) ablated the blockade
activity and the exchange of three amino acids (GII.4.2006/2009A) lessened the blockade activity for GII.4.2006.G2, GII.4.2006.G3, GII.4.2006.G4, and
GII.4.2006.G6 similarly to each other. (B) The exchange of five amino acids (GII.4.2006/1987A) ablated the blockade activity and the exchange of three amino
acids (GII.4.2006/2009A) did not significantly change the blockade activity of GII.4.2006.G7. (C) The exchange of any epitope A amino acids had no impact on
blockade activity on GII.4.2002.G5 or MBS224P.
TABLE 2 Mean blockade EC50 for each MAb tested
MAb
Mean VLP EC50 (g/ml)
a
GII.4.1987 GII.4.2006/1987A GII.4.2006 GII.4.2006/2009A GII.4.2009
GII.4.2006.G2 2 2 0.1032 (0.0863–0.1234) 0.4396 (0.5020–0.3849) 3.077 (2.472–3.8310)
GII.4.2006.G3 2 2 0.0487 (0.0398–0.0596) 0.1573 (0.1405–0.1762) 0.0480 (0.0407–0.0566)
GII.4.2006.G4 2 2 0.0303 (0.0238–0.0393) 0.0699 (0.0624–0.0782) 0.0270 (0.0227–0.0321)
GII.4.2006.G6 2 2 0.0253 (0.0189–0.0338) 0.2369 (0.2105–0.2666) 0.0689 (0.0569–0.0833)
GII.4.2006.G7 2 2 0.1034 (0.0675–0.1584) 0.1692 (0.1440–0.1987) 0.0456 (0.0411–0.0506)
GII.4.2002.G5 2 2 2 2 0.1383 (0.1248–0.1534)
MBS224P 2 2 2 2 0.1426 (0.1091–0.1863)
a The 95% CI is indicated in parentheses.
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had no impact on blockade activity of NO66, NO193, and NO224,
indicating that these MAbs do not target epitope A (Fig. 5C and
Table 3).
Epitope A is a primary target for blockade antibodies in hu-
man polyclonal sera following GII.4.2009 New Orleans infec-
tion. Mouse MAbs to GII.4.2006 and 2009 identified blockade
epitope A as an important distinguishing feature between these
two GII.4 strains (Fig. 6). To determine the impact epitope A may
have on the human polyclonal antibody response to NoV infec-
tion, we compared VLP blockade activity of convalescent-phase
serum collected from individuals infected with GII.4.2009 (Fig. 7).
GII.4.2009 convalescent-phase serum blocked GII.4.2006 (mean
EC50 	 0.0205 g/ml, 95% CI 	 0.0154 to 0.0273 g/ml),
GII.4.2006/2009A (mean EC50 	 0.0163 g/ml, 95% CI 	 0.0121
to 0.0221 g/ml), and GII.4.2009 (mean EC50 	 0.0160 g/ml,
95% CI 	 0.0131 to 0.0196 g/ml) VLPs similarly. Significantly
more serum was needed to block GII.4.1987 (mean EC50 	 0.0369
g/ml, 95% CI 	 0.0284 to 0.0479 g/ml) (P  0.05). Exchange of
the 1987 epitope A amino acids into GII.4.2006 (GII.4.2006/
1987A) significantly decreased the serum blockade activity by 38%
compared to GII.4.2006 and reconstituted levels similar to
GII.4.1987 blockade (mean EC50 	 0.0329 g/ml, 95% CI 	
FIG 4 Anti-GII.4.2009 MAbs recognize blockade epitopes and distinguish
GII.4.2009 from GII.4.2006. MAbs against GII.4.2009 were assayed for ability
to block VLP interaction with carbohydrate ligand. Sigmoidal curves were fit
to the mean percent control binding (the percentage of VLP bound to PGM in
the presence of antibody pretreatment compared to the amount of VLP bound
in the absence of antibody pretreatment), and the mean EC50 (g/ml) titer for
blockade of GII.4.2006 Minerva () and GII.4.2009 New Orleans (Œ) was
calculated. Error bars represent the 95% CI. *, The mean EC50 blockade titer
for GII.4.2006 is significantly different from the mean EC50 for GII.4.2009.
Nonblockade MAbs were assigned an EC50 of 5 g/ml for statistical analysis
and are noted on the graph by data markers above the upper limit of detection
(dashed line) for visual comparison.
FIG 5 GII.4.2009 blockade MAbs recognition of epitope A. MAbs against GII.4.2009 were assayed for ability to block VLP interaction with carbohydrate ligand.
Sigmoidal curves were fit to the mean percent control binding (the percentage of VLP bound to PGM in the presence of antibody pretreatment compared to the
amount of VLP bound in the absence of antibody pretreatment), and the mean EC50 titer was calculated. Error bars represent the 95% CI. *, The mean EC50
blockade titer significantly different from the mean EC50 for GII.4.2009. Nonblockade MAbs were assigned an EC50 of 5 g/ml for statistical analysis and are
noted by data markers above the upper limit of detection (dashed line) for visual comparison. The mean EC50 for blockade of epitope-exchanged VLPs identified
three epitope A reactivity pattern. (A) The exchange of five amino acids ablated the blockade activity and the exchange of three amino acids lessened the blockade
activity of NO37. (B) The exchange of five amino acids ablated the blockade activity and the exchange of three amino acids did not significantly change the
blockade activity of NO52. (C) The exchange of epitope A amino acids had no impact on the blockade activity of NO66, NO193, and NO224.
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0.0277 to 0.0398 g/ml). Conversely, exchange of the 2006
epitope A amino acids into GII.4.1987 (GII.4.1987/2006A) signif-
icantly increased the serum blockade activity by 37% compared to
GII.4.1987 and reconstituted levels similar to GII.4.2006 blockade
(mean EC50 	 0.0234 g/ml, 95% CI 	 0.0189 to 0.0290 g/ml).
These data indicate that ca. 40% of the polyclonal antibody re-
sponse to GII.4.2009 infection is directed against epitope A.
DISCUSSION
GII.4 NoV strains have circulated worldwide for at least the past 2
decades, despite high population seroprevalence, leading some to
conclude that NoVs induce only short-term or nonprotective im-
mune responses that allow repeated strain infection. However, the
detailed study of GII.4 strains that circulated from 1987 until 2012
at the bioinformatics level suggests that the GII.4 strains are com-
plex and divergent from each other, as new strains emerge and
replace ancestral strains. The viral evolution identified by bioin-
formatics has been confirmed by experimental data indicating
that different GII.4 strains exhibit different RNA-dependent RNA
polymerase rates (24), ligand-binding properties (16, 28), and an-
tigenicity (16, 20, 34). Specifically, new GII.4 norovirus strain
emergence is associated with changes in antibody blockade
epitopes (20–22), supporting the hypothesis that GII.4 NoV per-
sistence in the human population is driven by viral evolution that
results in antigenic drift and escape from herd immunity.
GII.4.2009 New Orleans is the first significant GII.4 strain to
emerge since the pandemic GII.4.2006 Minerva strain (42) and the
first since we developed a panel of MAbs that recognize GII.4
blockade epitopes, providing an opportunity to test this hypoth-
esis in the context of a newly emerged, currently circulating strain.
GII.4.2006 and GII.4.2009 share 88% sequence similarity in
the major capsid protein, explaining the high degree of similarity
between the strains based on EIA reactivity to MAbs since only 4 of
the 19 MAbs tested reacted with one but not the other VLP (Table
1 and data not shown). Reactivity to GII.4.2006 but not GII.4.2009
by MBS223P, a nonblockade antibody, suggests the strains differ
antigenically in at least one nonblockade epitope that remains
unidentified. Importantly, 10 of the 12 blockade MAbs tested dif-
ferentiated GII.4.2006 from GII.4.2009, as defined by statistically
significant differences in blockade titer (Fig. 1 and 4). These data
support the hypothesis that the emergence of GII.4.2009 is asso-
ciated with changes in blockade/neutralizing epitopes and subse-
quent loss of protective herd immunity, as previously described
TABLE 3 Mean EC50 for each GII.4.2009 New Orleans antibody tested
MAb
Mean VLP EC50 (g/ml)
a
GII.4.1987 GII.4.2006/1987A GII.4.2006 GII.4.2006/2009A GII.4.2009
NO37 2 2 0.1990 (0.1438–0.2754) 0.1628 (0.2527–0.1049) 0.0641 (0.0504–0.0816)
NO52 2 2 2.6560 (2.1970–3.2120) 0.0885 (0.0690–0.1137) 0.0508 (0.0401–0.0642)
NO66 2 2 2 2 0.1314 (0.1013–0.1774)
NO193 2 2 2 2 0.2821 (0.2395–0.3322)
NO224 2 2 2 2 0.1426 (0.1091–0.1863)
a The 95% CI is indicated in parentheses.
FIG 6 Summary of GII.4 MAb epitopes described in the present study. Anti-
body epitopes were determined to be conformational or linear based on West-
ern blot reactivity. Binding of seven of the MAbs was dependent upon epitope
A residues (light gray boxes). The impact of amino acids that comprise epitope
A on each MAb were designated as either essential for blockade activity (dark
gray boxes) or sufficient for complete blockade activity (black boxes) or had no
effect on blockade activity (white boxes) as described in Fig. 3 and 5.
FIG 7 Epitope A constitutes 40% of the polyclonal blockade antibody re-
sponse in NoV outbreak human convalescent-phase serum. Convalescent se-
rum samples collected from eight GII.4.2009-infected subjects were assayed
for ability to block VLP interaction with the carbohydrate ligand. Sigmoidal
curves were fit to the mean percent control binding (the percentage of VLP
bound to PGM in the presence of antibody pretreatment compared to the
amount of VLP bound in the absence of antibody pretreatment), and the mean
EC50 (percent serum) titer for blockade of each VLP was calculated. Error bars
represent 95% CI. *, The VLP mean EC50 blockade titer is significantly differ-
ent from the mean EC50 for GII.4.2009. The exchange of epitope A between the
GII.4.1987 and GII.4.2006 backbones resulted in significant changes (40%)
in the EC50 titer for both VLPs.
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for other GII.4 strains (16, 20, 22, 34) and other RNA viruses such
as influenza virus (54–56) and HIV and HCV (57).
Epitope A, a previously identified blockade epitope (20, 22),
differs between GII.4.2006 and GII.4.2009. Predicted epitope A is
conformation dependent and consists minimally of varying
amino acid residues 294, 296, 297, 298, 368, and 372. Amino acid
combinations including these residues have been predicted to
form antibody epitopes by other groups as well (45, 46). Epitope A
is targeted by a significant portion of isolated MAbs as well as
polyclonal antibody responses elicited in both norovirus-immu-
nized mice (22) and infected humans (Fig. 7) (20), indicating a
primary function in the overall anti-GII.4 antibody response.
Three of the six epitope A amino acids vary between GII.4.2006
and GII.4.2009: A294P, S368A, and E372D. The blockade activi-
ties of seven of the MAbs studied have been impacted by residue
variation in epitope A. By comparing MAb blockade of GII.4.2006
with different versions of epitope A, we identified several epitope
binding patterns. GII.4.2006.G2, GII.4.2006.G3, GII.4.2006.G4,
GII.4.2006.G6, and GII.4.2006.G7 and NO37 and NO52 each
completely lost GII.4.2006 blockade ability when the GII.4.2006
epitope A was exchanged with epitope A residues found in
GII.4.1987. GII.4.2006.G2, GII.4.2006.G3, GII.4.2006.G4, and
GII.4.2006.G6 each regained significantly more blockade activity
when only amino acids 294, 368, and 372 were modified, com-
pared to homotypic VLP blockade, suggesting that residues 296,
297, and 298 are essential for binding to epitope A for these MAbs.
However, none of these MAbs detect VLP by Western blot analy-
sis, despite the linear nature of this predicted binding region. Only
NO37, which blocked GII.4.2006 and GII.4.2006/2009A similarly
detected VLP by Western blotting, confirming that the linear se-
quence of residues 296, 297, and 298 is not only essential but
sufficient for binding of this MAb. Similarly, GII.4.2006.G7
epitope A binding pattern is characterized by no change in block-
ade activity when 294, 368, and 372 were changed compared to
homotypic VLP blockade activity. However, this MAb did not
detect VLPs by Western blotting. NO52 provides an additional
epitope A binding pattern characterized by almost all of the block-
ade activity conferred by the conformational amino acids 294,
368, and 372. These varied patterns of epitope A reactivity suggest
that amino acids 294, 296 to 298, 368, and 372 actually constitute
several distinct, overlapping blockade antibody epitopes, and our
panel of MAbs consists of individual antibodies that bind to dif-
ferent combinations of amino acids that include components of
epitope A, in particular residues 296 to 298. This suggestion is
supported by the diverse EIA reactivity patterns documented for
several of these MAbs now defined as epitope A dependent. Inter-
estingly, these diverse strain EIA reactivity patterns coupled with
highly selective blockade patterns are contrary to findings with
human MAbs that recognize epitope A. Previous studies with hu-
man MAbs demonstrated that epitope A has a complex reactivity
pattern between strains (20). Three of seven anti-GII.4 MAbs de-
veloped from a healthy individual of unknown NoV exposure
history were targeted to epitope A. One MAb only recognized and
blocked epitope A as it is presented in the early strains GII.4.1987
and GII.4.1997. Two other MAbs only recognized and blocked
epitope A as it is presented in GII.4.2006 and GII.4.2009, although
significantly more antibody was needed to block GII.4.2009 than
was needed to block GII.4.2006. Similar but very limited cross-
strain blockade activity was also shown for mouse MAbs that bind
to epitope A (22, 34), but, surprisingly, mouse MAbs targeting
epitope A display a wider EIA binding profile than human MAbs
directed to epitope A (22, 34), possibly suggesting a difference in
norovirus antibody specificity between antibodies that result from
hyperimmunization of mice with VLP and antibodies generated
as the result of a life-time of norovirus infection. Crystal structures
of GII.4-MAb complexes are needed to fully understand these
complex reactivity patterns.
Epitope A is continuing to evolve, likely in response to protec-
tive herd immunity, and the data presented here suggest that a
surveillance system that monitored changes in epitope A may be
an effective predictor of new norovirus strain emergence. Al-
though, at this time, it is unclear exactly how many or which
amino acids within epitope A would need to change to result in
complete escape from anti-GII.4.2006 immunity, clearly changing
five of the six amino acids (294, 297, 298, 368, and 372) results in
complete loss of blockade activity of all of the MAbs that are im-
pacted by epitope A sequence while changing only three amino
acids (294, 368, and 372) had anywhere from no effect to almost
complete restoration of the blockade activity, depending on the
antibody tested. Comparison of a large panel of MAbs for block-
ade activity of both GII.4.2006 and GII.4.2009 indicated that
GII.4.2009 is an intermediate escape variant, sensitive to blockade
by some but not all anti-GII.4.2006 MAbs. These partial epitope
changes may explain the documented transition from GII.4.2006
to GII.4.2009 as the primary cause of norovirus outbreaks in the
absence of an increase in the total number of norovirus outbreaks
(43).
The continued viral adaptation of blockade epitopes, including
epitope A, will require development of proactive norovirus sur-
veillance systems coupled with a formulation-adaptable vaccine to
provide protection from norovirus infection, not unlike the suc-
cessful approach used for global control of influenza virus. Noro-
virus surveillance systems have already been established in Eu-
rope, Japan, and the United States and shown to be able to rapidly
detect newly emerging strains (42). Mapping of the crucial
epitopes for virus neutralization will facilitate the predicative
power of these surveillance systems and provide potential vaccine
targets.
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